A true end-to-end supply chain management model NMDP BioTherapies enables our partners to get their cell therapies to patients faster. We’re experts in autologous cell therapy supply chains, providing seamless coordination from scheduling with stakeholders to collection and delivery to the patient. Leveraging our extensive experience, we implement proven supply chain solutions, saving clients the…
The newly formed NMDP BioTherapies Cord Blood Bank Alliance has the potential to open the door to new cell therapies by expanding awareness and enabling researchers and developers to more easily identify and access cord blood units for their work.
Cord blood’s unique, naïve biology often comes up as a reason to use it as an allogeneic cell therapy source material. But as Cleveland Cord Blood Center Executive Director Marcie Finney explains, there are 4 non-biological factors cell and gene therapy developers should also consider.
Allogeneic cell therapy development has been top-of-mind in recent years as autologous cell therapies see continued success. For more than three decades, the largest group of HLA experts in the world has worked to create a unique cell source selection expertise. That expertise holds value for allogeneic cell and gene therapy developers, too.
The movement of fresh cellular starting material or a manufactured cell and gene therapy is a critical and time-sensitive piece of the supply chain ecosystem. At Be The Match BioTherapies®, these transports are coordinated and monitored by experienced logistics coordinators. In many cases, it’s our volunteer couriers who hand carry and deliver these products. “Our…
As a cell and gene therapy developer, your cell collection protocol requirements and specifications will impact your apheresis center network selection strategy and your ability to efficiently scale your processes. Any time your protocols or processes differ from those in place at a center, there are likely implications for training, forms and standard operating procedures (SOPs), which can delay your first collection.
As your cell or gene therapy moves toward commercialization, supply chain readiness is critical. But what does it take to develop a successful supply chain strategy to support a commercial launch? Orchard Therapeutics and Be The Match BioTherapies® have first-hand experience.
After raising a record $19.9 billion in funding in 2020, doubling the previous year, the cell and gene therapy industry shows no signs of slowing down. Forecasters predict more record growth this year, especially in terms of regulatory decisions; at least nine new products have been approved or are up for approval in the United…
Allogeneic cell therapies are inherently complex. But they also hold the potential to scale to treat large segments of the population. Martin Maiers, MS, is the Vice President of Innovation at the National Marrow Donor Program® (NMDP)/Be The Match®. He and his team develop software and analytical methods used to predict factors that can impact…